CN110167968B - 针对her3的抗原结合蛋白 - Google Patents

针对her3的抗原结合蛋白 Download PDF

Info

Publication number
CN110167968B
CN110167968B CN201780057182.8A CN201780057182A CN110167968B CN 110167968 B CN110167968 B CN 110167968B CN 201780057182 A CN201780057182 A CN 201780057182A CN 110167968 B CN110167968 B CN 110167968B
Authority
CN
China
Prior art keywords
antigen binding
her3
seq
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780057182.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167968A (zh
Inventor
罗兰·康特曼
丽莎·施米特
迈克·赫特
奥利弗·塞弗特
莫尼洛拉·奥莱奥耶
迈克尔·于斯特
斯蒂芬·迪尤贝尔
乔纳斯·赞特托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Stuttgart
Original Assignee
Universitaet Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Stuttgart filed Critical Universitaet Stuttgart
Publication of CN110167968A publication Critical patent/CN110167968A/zh
Application granted granted Critical
Publication of CN110167968B publication Critical patent/CN110167968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780057182.8A 2016-09-15 2017-09-15 针对her3的抗原结合蛋白 Active CN110167968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16188871 2016-09-15
EP16188871.4 2016-09-15
PCT/EP2017/073328 WO2018050848A1 (en) 2016-09-15 2017-09-15 Antigen binding protein against her3

Publications (2)

Publication Number Publication Date
CN110167968A CN110167968A (zh) 2019-08-23
CN110167968B true CN110167968B (zh) 2023-11-28

Family

ID=57017956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780057182.8A Active CN110167968B (zh) 2016-09-15 2017-09-15 针对her3的抗原结合蛋白

Country Status (13)

Country Link
US (1) US11008402B2 (https=)
EP (1) EP3512886B1 (https=)
JP (2) JP7203426B2 (https=)
KR (1) KR102469700B1 (https=)
CN (1) CN110167968B (https=)
AU (1) AU2017327769B2 (https=)
BR (1) BR112019005001A2 (https=)
CA (1) CA3033694C (https=)
DK (1) DK3512886T3 (https=)
ES (1) ES3037145T3 (https=)
MX (1) MX2019002664A (https=)
WO (1) WO2018050848A1 (https=)
ZA (1) ZA201901379B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018414456B2 (en) * 2018-03-22 2025-09-11 Universität Stuttgart Multivalent binding molecules
FI3774859T3 (fi) 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
MX2022003507A (es) * 2019-09-25 2022-04-25 Univ Stuttgart Modulos de union que comprenden dominios ehd2 modificados.
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
MX2023003304A (es) * 2020-09-21 2023-05-09 Systimmune Inc Complejo de union de egfr y metodo de fabricacion y uso del mismo.
JP7847132B2 (ja) * 2020-10-14 2026-04-16 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途
WO2023165475A1 (zh) * 2022-03-03 2023-09-07 四川科伦博泰生物医药股份有限公司 Her3结合蛋白及其用途
CN115057946B (zh) * 2022-06-30 2023-05-16 四川省医学科学院·四川省人民医院 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用
EP4680648A1 (en) * 2023-03-17 2026-01-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her3 and anti-met antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1650011A (zh) * 2002-03-26 2005-08-03 上海泽生科技开发有限公司 Erbb3用于肿瘤治疗的方法和组合物
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
CN104271761A (zh) * 2011-11-30 2015-01-07 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US9346890B2 (en) * 2012-10-25 2016-05-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ErbB3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1650011A (zh) * 2002-03-26 2005-08-03 上海泽生科技开发有限公司 Erbb3用于肿瘤治疗的方法和组合物
CN104271761A (zh) * 2011-11-30 2015-01-07 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin;GARNER,A.等;《CANCER RES.》;20131001;第73卷(第19期);第4-6页 *
靶向HER3逆转EGFR抑制剂耐药机制的研究进展;李真真等;《中国肿瘤》;20160605(第06期);全文 *

Also Published As

Publication number Publication date
BR112019005001A2 (pt) 2019-06-04
JP7203426B2 (ja) 2023-01-13
ES3037145T3 (en) 2025-09-29
ZA201901379B (en) 2024-06-26
WO2018050848A1 (en) 2018-03-22
EP3512886B1 (en) 2025-06-11
JP2022169589A (ja) 2022-11-09
CN110167968A (zh) 2019-08-23
MX2019002664A (es) 2019-09-26
KR20190065259A (ko) 2019-06-11
CA3033694A1 (en) 2018-03-22
AU2017327769A1 (en) 2019-03-07
US11008402B2 (en) 2021-05-18
JP2020501509A (ja) 2020-01-23
DK3512886T3 (da) 2025-08-18
AU2017327769B2 (en) 2023-12-21
JP7638531B2 (ja) 2025-03-04
CA3033694C (en) 2023-06-27
KR102469700B1 (ko) 2022-11-23
EP3512886A1 (en) 2019-07-24
US20190194350A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CN110167968B (zh) 针对her3的抗原结合蛋白
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
US20210317204A1 (en) Bi-specific binding molecules
WO2023020621A1 (en) Anti-ccr8 antibodies and uses thereof
JP2022545439A (ja) 新規ｉｌ－２１プロドラッグおよびその使用方法
Croasdale et al. Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
JP2025503402A5 (https=)
CN114040926A (zh) 结合cd123的多肽及其用途
CA3043277A1 (en) Anti-cd46 antibodies and methods of use
US20190351024A1 (en) Immunocytokines with progressive activation mechanism
JP2022548728A (ja) 抗ｐｔｃｒａ抗体－薬物コンジュゲートおよびその使用
JP2026506762A (ja) 薬剤、方法、およびそれらの使用
US20250009788A1 (en) Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
CN114025795B (zh) 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法
JP2024546106A5 (https=)
EP4556494A1 (en) Anti-ror1 antibody, bispecific antibody comprising same, and uses thereof
CN120882866A (zh) Alpp特异性变体抗原结合分子
WO2024165403A1 (en) Anti-cea antibodies
WO2025106822A2 (en) P2ry8 antibodies and methods of treating cancer
AU2024379016A1 (en) P2ry8 antibodies and methods of treating cancer
CN121712808A (zh) 蛋白酶可活化的Fc结构域结合分子
CN117794953A (zh) 双特异性抗体及使用方法
HK40108333A (zh) 双特异性抗体及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Roland Contman

Inventor after: Lisa Schmidt

Inventor after: Huet Mickael

Inventor after: Oliver Seifert

Inventor after: Monilora Oleoye

Inventor after: Michael Hurst

Inventor after: Stephen Diubel

Inventor after: Jonas Zanterto

Inventor before: Roland Contman

Inventor before: Lisa Schmidt

Inventor before: Mike Hurt

Inventor before: Oliver Seifert

Inventor before: Monilora Oleoye

Inventor before: Michael Hurst

Inventor before: Stephen Diubel

Inventor before: Jonas Zanterto

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380404